Bristol-Myers Squibb Company (NYSE: BMY) has today announced that on 1 July 2010 the European Commission approved a new indication for ORENCIA® (abatacept), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a TNF-alpha inhibitor.
“There is a growing body of evidence to show that earlier use of ORENCIA may have significant benefits for patients - for both short-term and long-term efficacy. This new indication means patients have the potential to benefit sooner from incremental improvements in function and quality of life provided by ORENCIA.”
"This is a very welcome decision from the European Commission and one which will potentially have a positive impact on treatment outcomes for RA patients who have already experienced inadequate response to a first DMARD," said Dr. Manuela Le Bars, European Medical Lead for Immunoscience, Bristol-Myers Squibb. "There is a growing body of evidence to show that earlier use of ORENCIA may have significant benefits for patients - for both short-term and long-term efficacy. This new indication means patients have the potential to benefit sooner from incremental improvements in function and quality of life provided by ORENCIA."
Tryptophan digestion by gut microbiome spurs arthritis inflammation